- Home
- PLG vs CTNM Comparison
PLG vs CTNM Comparison
Compare PLG & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLG
- CTNM
- Stock Information
- Founded
- PLG 2000
- CTNM 2009
- Country
- PLG Canada
- CTNM United States
- Employees
- PLG N/A
- CTNM N/A
- Industry
- PLG
- CTNM
- Sector
- PLG
- CTNM
- Exchange
- PLG Nasdaq
- CTNM Nasdaq
- Market Cap
- PLG 217.6M
- CTNM 248.7M
- IPO Year
- PLG N/A
- CTNM 2024
- Fundamental
- Price
- PLG $2.78
- CTNM $11.21
- Analyst Decision
- PLG
- CTNM Strong Buy
- Analyst Count
- PLG 0
- CTNM 5
- Target Price
- PLG N/A
- CTNM $22.20
- AVG Volume (30 Days)
- PLG 3.3M
- CTNM 201.6K
- Earning Date
- PLG 11-25-2025
- CTNM 11-05-2025
- Dividend Yield
- PLG N/A
- CTNM N/A
- EPS Growth
- PLG N/A
- CTNM N/A
- EPS
- PLG N/A
- CTNM N/A
- Revenue
- PLG N/A
- CTNM N/A
- Revenue This Year
- PLG N/A
- CTNM N/A
- Revenue Next Year
- PLG N/A
- CTNM N/A
- P/E Ratio
- PLG N/A
- CTNM N/A
- Revenue Growth
- PLG N/A
- CTNM N/A
- 52 Week Low
- PLG $0.99
- CTNM $3.35
- 52 Week High
- PLG $3.07
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- PLG 78.59
- CTNM 55.51
- Support Level
- PLG $2.43
- CTNM $10.65
- Resistance Level
- PLG $3.07
- CTNM $12.14
- Average True Range (ATR)
- PLG 0.24
- CTNM 0.97
- MACD
- PLG 0.05
- CTNM -0.23
- Stochastic Oscillator
- PLG 79.63
- CTNM 32.20
About PLG Platinum Group Metals Ltd. (Canada)
Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.